A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis.
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2012
At a glance
- Drugs Teplizumab; Teplizumab
- Indications Plaque psoriasis
- Focus Adverse reactions
- 18 Apr 2012 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 18 Apr 2012 Actual patients number is 1 as reported by ClinicalTrials.gov.
- 24 Aug 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.